Shots:The company has begun P-III (ECLIPSE) trial of ASP-1929 (photoimmunotherapy) + Keytruda for HNSCC, with first patient treated at a site across the US. Recruitment is underway in Japan, Taiwan & other regions
This global study aims at assessing safety & efficacy of ASP-1929 + Keytruda vs Keytruda-based SoC as a 1L treatment…
Shots: Laurent spoke about the study design of its nanoparticle therapy to enhance the cancer-killing effect of radiation, which was presented at ASCO 2022Laurent also highlighted how this nanoparticle therapy can be a potential radio enhancer in various tumor types and across lines of therapyThe interview summarizes Nanobiotix’s vision to advance nanoparticles across…
